



## **BioInvent's partner Oxurion NV has reported topline month 3 results of Phase IIa Study Evaluating THR-317 (anti-PLGF), in Combination with Ranibizumab, for DME**

**Lund, Sweden – August 20, 2019** – BioInvent International AB's (publ) (OMXS: BINV) partner Oxurion NV has today reported topline data from a Phase IIa study evaluating THR-317, a humanized antibody against placental growth factor (PlGF), in combination with anti-VEGF (ranibizumab), an anti-vascular endothelial growth factor (VEGF) antibody, for the treatment of Diabetic Macular Edema (DME).

- Combination therapy did not show increase in best corrected visual acuity (BCVA) in the overall population at Month 3.
- Certain improvement in mean BCVA at Month 3 observed with the combination therapy in 2 pre-specified subgroups:
  - poor (or non) responders to prior anti-VEGF
  - patients with poor vision - baseline BCVA  $\leq 65$  letters.
- Topline data confirm THR-317 in combination with ranibizumab is safe and well-tolerated.

In 2017, Oxurion NV gained full and exclusive ownership of THR-317 for development and commercialization in all non-oncology indications. In exchange, BioInvent is entitled to five percent of the program's economic value.

For further information, see Oxurion's press release of August 20, 2019 ([www.oxurion.com](http://www.oxurion.com)).

### **About BioInvent**

BioInvent International AB (OMXS: BINV) is focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies to treat cancer. The Company's lead program BI-1206, is currently in Phase I/II for non-Hodgkin lymphoma and chronic lymphatic leukemia. BioInvent's pre-clinical portfolio is focused on targeting key immune suppressive cells and pathways of the tumor microenvironment, including regulatory T cells, tumor-associated myeloid cells and mechanisms of antibody drug-resistance. The Company has a strategic research collaboration with Pfizer Inc., and partnerships with Transgene, Bayer Pharma, Daiichi Sankyo, and Mitsubishi Tanabe Pharma. BioInvent generates near term revenues from its fully integrated manufacturing unit producing antibodies for third parties for research through to late-stage clinical trials. More information is available at [www.bioinvent.com](http://www.bioinvent.com).

### **For further information, please contact:**

Martin Welschhof, CEO  
+46 (0)46 286 85 50  
[martin.welschhof@bioinvent.com](mailto:martin.welschhof@bioinvent.com)

Hans Herklots, LifeSci Advisors  
+41 79 598 71 49  
[hherklots@lifesciadvisors.com](mailto:hherklots@lifesciadvisors.com)

### **BioInvent International AB (publ)**

Co. Reg. No. Org nr: 556537-7263  
Visiting address: Sölvegatan 41  
Mailing address: 223 70 LUND  
Phone: +46 (0)46 286 85 50  
[www.bioinvent.com](http://www.bioinvent.com)

*The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.*